Phase-I trial of 4-demethoxydaunorubicin in acute leukaemias.
Eleven patients with heavily pretreated acute leukaemia were treated with 4-demethoxydaunorubicin. Dosages were escalated from 7 mg/m2/d to 15 mg/m2/d for 3 consecutive days. One patient achieved a partial remission and antitumor activity was seen in most other patients. Stomatitis was dose-limiting at 15 mg/m2. Phase II trials are warranted and we propose a schedule of 12 mg/m2/d for 3 consecutive days.
D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000633:toxicity*; D001853:Bone Marrow / Q000187:drug effects; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000633:toxicity; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D015255:Idarubicin; D003630:Daunorubicin